Table 1.
Demographic and Clinical Characteristics for 44 Liver Disease Progressor and Nonprogressor Study Subjects Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus in Whom Liver Disease Did or Did Not Progress
| Characteristic | Progressors (n = 21) | Nonprogressors (n = 23) | Univariate OR (95% CI) | Pa |
|---|---|---|---|---|
| Age at T1, y | 42.4 ± 7.4 | 40.8 ± 5.7 | … | .44 |
| Interval between T1 and T3, y | 4.8 ± 0.62 | 5.0 ± 0.33 | … | .17b |
| Race/ethnicity | ||||
| White, non-Hispanic | 8 (38.1) | 8 (34.8) | 1.04 (.31–3.52) | .62c |
| White, Hispanic | 0 (0) | 1 (4.3) | … | |
| African American, non-Hispanic | 13 (61.9) | 14 (60.9) | Reference | |
| CD4+ T-cell count, cells/mm3 | ||||
| T1 | 421.0 ± 267.8 | 526.0 ± 343.8 | … | .27b |
| All study visits (n = 131)d | 371.0 ± 271.4 | 491.7 ± 299.8 | … | .02b |
| CD4+ T-cell percentage | ||||
| T1 | 20.3 ± 8.5 | 27.0 ± 10.3 | … | .02b |
| All study visits (n = 131)d | 20.5 ± 10.4 | 27.4 ± 9.4 | … | .0001b |
| HIV RNA load, copies/mL | ||||
| T1 | 15 420.5 ± 30 190.4 | 12 156.1 ± 22 007.6 | … | .73b |
| All study visits (n = 131)d | 12 7894 ± 613 973 | 38 836.8 ± 185 216 | … | .28b |
| Visits during which HIV RNA load was undetectablee | 37/63 (58.7) | 36/68e (52.9) | 1.27 (.63–2.53) | .60 |
| HIV RNA load at T1 for those with a detectable HIV RNA load (n = 26) | 24 667.5 ± 36 585.8 | 19 079.3 ± 26 179.5 | … | .65b |
| HIV RNA load for those with a detectable HIV RNA load (n = 73)e | 213 830 ± 787 349 | 72 851.7 ± 251 275 | … | .31b |
| Visits during which HAART was usede | 36/63 (57.1) | 28/69 (40.6) | 1.95 (.98–3.90) | .08 |
| Maximum alcohol use, drinks/wk | ||||
| None | 7 (33.3) | 4 (17.4) | … | .16c |
| <8 | 5 (23.8) | 13 (56.5) | … | |
| 8–14 | 2 (9.5) | 2 (8.7) | … | |
| ≥15 | 7 (33.3) | 4 (17.4) | … | |
| Liver disease ascertainment | ||||
| By liver biopsy | 8 (38.1) | 8 (34.8) | … | |
| By confirmation of liver-associated death | 6 (28.6) | … | ||
| By serum marker analysis | 7 (33.3) | 15 (65.2) | ||
| Any hepatitis C treatment | 1 (4.8) | 1 (4.4) | 1.10 (.06–18.77) | >.999 |
| IDU since most recent visit before T1 | 2 (9.5) | 5 (21.7) | 0.38 (.07–2.21) | .42 |
| Cocaine use since most recent visit before T1 | 8 (38.1) | 6 (26.1) | 1.74 (.48–6.28) | .52 |
Data are mean ± SD or no. (%) of subjects, unless otherwise indicated. See Methods for definitions of T1 and T3.
Abbreviations: CI, confidence interval; HAART, highly active antiretroviral therapy; IDU, injection drug use; OR, odds ratio.
a By the Fisher exact test, unless otherwise indicated.
b By the t test.
c By global χ2 analysis.
d One subject did not have data for 1 visit.
e Data are for 3 visits per subject.